Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.

  • Cerezo-Wallis, Daniela
  • Contreras-Alcalde, Marta
  • Troulé, Kevin
  • Catena, Xavier
  • Mucientes, Cynthia
  • Calvo, Tonantzin G
  • Cañón, Estela
  • Tejedo, Cristina
  • Pennacchi, Paula C
  • Hogan, Sabrina
  • Kölblinger, Peter
  • Tejero, Héctor
  • Chen, Andrew X
  • Ibarz, Nuria
  • Graña-Castro, Osvaldo
  • Martinez Garcia, Maria Dolores
  • Muñoz, Javier
  • Ortiz-Romero, Pablo
  • Rodriguez-Peralto, José L
  • Gómez-López, Gonzalo
  • Al-Shahrour, Fatima
  • Rabadán, Raúl
  • Levesque, Mitchell P
  • Olmeda, David
  • Soengas, MS
An open question in aggressive cancers such as melanoma is how malignant cells can shift the immune system to pro-tumorigenic functions. Here we identify midkine (MDK) as a melanoma-secreted driver of an inflamed, but immune evasive, microenvironment that defines poor patient prognosis and resistance to immune checkpoint blockade. Mechanistically, MDK was found to control the transcriptome of melanoma cells, allowing for coordinated activation of nuclear factor-κB and downregulation of interferon-associated pathways. The resulting MDK-modulated secretome educated macrophages towards tolerant phenotypes that promoted CD8+ T cell dysfunction. In contrast, genetic targeting of MDK sensitized melanoma cells to anti-PD-1/anti-PD-L1 treatment. Emphasizing the translational relevance of these findings, the expression profile of MDK-depleted tumors was enriched in key indicators of a good response to immune checkpoint blockers in independent patient cohorts. Together, these data reveal that MDK acts as an internal modulator of autocrine and paracrine signals that maintain immune suppression in aggressive melanomas.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state

  • Cerezo-Wallis, Daniela
  • Contreras-Alcalde, Marta
  • Troulé, Kevin
  • Catena, Xavier
  • Mucientes, Cynthia
  • Calvo, Tonantzin G.
  • Cañón, Estela
  • Tejedo, Cristina
  • Pennacchi, Paula C.
  • Hogan , Sabrina
  • Kölblinger, Peter
  • Tejero, Héctor
  • Chen, Andrew X.
  • Ibarz, Nuria
  • Graña, Osvaldo
  • Martinez, Lola
  • Muñoz, Javier
  • Ortiz-Romero, Pablo
  • Rodríguez-Peralto, José L.
  • Gómez-López, Gonzalo
  • Al-Shahrour, Fátima
  • Rabadán, Raúl
  • Levesque, Mitchell P.
  • Olmeda, David
  • Soengas, María S.
An open question in aggressive cancers such as melanoma is how malignant cells can shift the immune system to pro-tumorigenic functions. Here we identify midkine (MDK) as a melanoma-secreted driver of an inflamed, but immune evasive, microenvironment that defines poor patient prognosis and resistance to immune checkpoint blockade. Mechanistically, MDK was found to control the transcriptome of melanoma cells, allowing for coordinated activation of nuclear factor-κB and downregulation of interferon-associated pathways. The resulting MDK-modulated secretome educated macrophages towards tolerant phenotypes that promoted CD8+ T cell dysfunction. In contrast, genetic targeting of MDK sensitized melanoma cells to anti-PD-1/ anti-PD-L1 treatment. Emphasizing the translational relevance of these findings, the expression profile of MDK-depleted tumors was enriched in key indicators of a good response to immune checkpoint blockers in independent patient cohorts. Together, these data reveal that MDK acts as an internal modulator of autocrine and paracrine signals that maintain immune suppression in aggressive melanomas., M.S.S. is funded by grants from the Spanish Ministry of Economy and Innovation (SAF2017-89533-R), Team Science and Established Investigator awards by the Melanoma Research Alliance, and grants from Worldwide Cancer Research and Fundación ‘La Caixa’ Health Research 2019. M.S.S., P.O.-R. and J.L.R.-P. are funded by a collaborative grant from the Asociación Española Contra el Cáncer (AECC). D.O. is funded by grants from the Spanish Ministry of Health (AES-PIS PI18/1057) and ‘Fundación BBVA-Becas Leonardo a Investigadores y Creadores Culturales 2018’. D.C.-W. was a recipient of a predoctoral fellowship from Fundación ‘La Caixa’ and is currently funded by the AECC. The CNIO Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. N.I. and J.M. are funded by SAF2013-45504-R (MINECO). J.M. is also supported by Ramón y Cajal Programme (MINECO) RYC-2012-10651. M.C.-A. and X.C. were funded by the Immutrain Marie Skłodowska-Curie ITN Grant. S.H. received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement number 641458., Peer reviewed